Skip to main content

Table 2 Adverse events associated with the first course of hepatic arterial infusion chemotherapy

From: Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial

No. (%) Grade 1 Grade 2 Grade 3 Grade 4 Total
Clinical
 Nausea/Vomiting 9 (17) 2 (4) 0 0 11(20)
 Anorexia 10 (19) 7 (13) 1(25) 0 18 (33)
 Fever 5 (9) 1 (25) 0 0 6 (11)
 Pain 11 (20) 0 0 0 11 (20)
 Fatigue 8 (15) 1(25) 0 0 9 (17)
 Diarrhea 0 1(25) 0 0 1(25)
Laboratory abnormalities
 Leucocyte count decrease 22 (41) 6 (11) 1(25) 0 29 (54)
 Neutrophil count decrease 10 (19) 2 (4) 0 0 12 (22)
 Anemia 26 (48) 7 (13) 2 (4) 0 35 (65)
 Platelet count decrease 22 (41) 9 (17) 4 (7) 0 35 (65)
 AST/ALT increase 24 (44) 4 (7) 4 (7) 0 32 (59)
 Creatinine increase 15 (28) 0 0 0 15 (28)
Total    12 (21.8) 0 (0)  
  1. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase